Skip to content
Home/Companies/Biotech/Caprion Biosciences

Caprion Biosciences

Biotech·Canada·Exited 2019·Held 3yr
Entry
2016
Hold
3yr
Exit
2019

Who owns Caprion Biosciences?

Caprion Biosciences is a Canadian Biotech company, now owned by Arsenal Capital Partners, which acquired it in 2019 from GHO Capital.

Hand-verified · updated 2026-07-07

Open JSON · CC-BY
GHO Capital
Investor
GHO Capital
GHO Capital Fund I LP · 2015 · Buyout

Key facts

HQCanada
SectorBiotech
StatusAcquired
Exit Type
Secondary
Buyer
Arsenal Capital Partners
Exit Year
2019

More from GHO Capital Fund I LP

Other portfolio companies in the same fund.

BioAgilytix
Exited 2021
BiotechUS· 2018
to Cinven
Linimed-Fazmed
Active
HealthcareGermany· 2018
VISUfarma
VISUfarma
Exited 2026
PharmaUK· 2016
to Lupin
DNA Diagnostics Center
Exited 2021
HealthcareUS· 2015
to Eurofins
Quotient Clinical
Active
PharmaUK· 2015
Quotient Sciences
Exited 2019
PharmaUK· 2015
to Permira

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Caprion Biosciences?

Caprion Biosciences is now owned by Arsenal Capital Partners, which acquired it in 2019 from GHO Capital.

When did Arsenal Capital Partners acquire Caprion Biosciences?

Arsenal Capital Partners acquired Caprion Biosciences in 2019, buying from GHO Capital.

Who did Caprion Biosciences sell to?

GHO Capital sold Caprion Biosciences to Arsenal Capital Partners in 2019 (Secondary).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue